Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Monday, Nov. 18, 2024, at 11:30 a.m. ET.

The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com. 

Investors:
Alex Braun
abraun@acumenpharm.com

Media: 
AcumenPR@westwicke.com 


Primary Logo

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  214.91
+1.87 (0.88%)
AAPL  258.10
+5.81 (2.30%)
AMD  235.53
+2.45 (1.05%)
BAC  51.81
+0.53 (1.04%)
GOOG  256.44
+2.65 (1.05%)
META  725.74
+8.83 (1.23%)
MSFT  515.27
+1.69 (0.33%)
NVDA  182.94
-0.28 (-0.15%)
ORCL  284.19
-7.12 (-2.44%)
TSLA  444.13
+4.82 (1.10%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.